A presumed case of Darbepoetin‐induced myocardial infarction in the patient with MDS‐RARS

Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zafar, Aneeqa Ahsan, Kouides, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141713/
https://www.ncbi.nlm.nih.gov/pubmed/32274030
http://dx.doi.org/10.1002/ccr3.2728
Descripción
Sumario:Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin‐stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality.

Ejemplares similares